Mayor's office contact:
Oct. 25, 2016
INDIANAPOLIS - Today, Indianapolis Mayor Joe Hogsett joined Chairman of the Roche Group Christoph Franz, global and local Roche leaders, and employees to lead a dedication ceremony at the Roche Diagnostics North American headquarters.
The ceremony celebrated the completion of the first phase of the Swiss-based company’s site transformation. Roche announced plans in June 2012 to invest more than $300 million over the next 10 years at its Indianapolis site. Since that time, the company has built five new buildings, refurbished existing buildings, made upgrades to IT infrastructure and increased investments in its next- generation diabetes care manufacturing technology.
“This site transformation represents a significant long-term investment by Roche in our Indianapolis campus, our people and also to the broader Central Indiana community,” said Christoph Franz, Chairman of the Roche Group Board of Directors. “We are especially proud of the design of these new buildings, which reflects our heritage as an innovative leader in healthcare."
Nearly 200 Indiana companies and contractors worked more than 1.3 million hours since 2012 to complete this first phase of the site transformation.
“Today’s dedication is another significant milestone in the long history of Roche in Indianapolis,” said Indianapolis Mayor Joe Hogsett. “Although based in Switzerland, Roche Diagnostics’ local founding and growth in Indianapolis is a true Hoosier success story. During the past 50 years, Roche has positioned itself as the U.S. and worldwide leader in in vitro diagnostics and I can’t wait to see what the next 50 years will bring.”
Roche Diagnostics has been part of the Indianapolis landscape since 1964 when it was founded as Bio- Dynamics and later acquired by Boehringer Mannheim Corporation in 1974. Roche acquired Boehringer Mannheim in 1998 and within three years became the world leader in diagnostics. Today, the company employs nearly 3,000 Hoosiers and more than 4,400 associates nationwide.
Timeline for new construction:
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.